Trade Report: The 2,160 Shares of Orthofix International NV (OFIX) are sold by JPMorgan Chase & Co.

The 2,160 Shares of Orthofix International NV (OFIX) are sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its stake in Orthofix International NV (NASDAQ:OFIX) by 1.0% during the second quarter, Holdings Channel reports. The firm owned 209,219 shares of the medical device company’s stock after selling 2,160 shares during the period. JPMorgan Chase & Co. owned approximately 1.15% of Orthofix International NV worth $8,872,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of OFIX. Norges Bank acquired a new position in shares of Orthofix International NV during the fourth quarter valued at about $9,643,000. TIAA CREF Investment Management LLC boosted its position in shares of Orthofix International NV by 4.7% in the first quarter. TIAA CREF Investment Management LLC now owns 95,843 shares of the medical device company’s stock valued at $3,979,000 after buying an additional 4,269 shares during the period. Algert Global LLC acquired a new position in shares of Orthofix International NV during the first quarter valued at about $373,000. Goldman Sachs Group Inc. boosted its position in shares of Orthofix International NV by 59.7% in the first quarter. Goldman Sachs Group Inc. now owns 65,550 shares of the medical device company’s stock valued at $2,721,000 after buying an additional 24,513 shares during the period. Finally, Bogle Investment Management L P DE boosted its position in shares of Orthofix International NV by 37.6% in the first quarter. Bogle Investment Management L P DE now owns 81,833 shares of the medical device company’s stock valued at $3,397,000 after buying an additional 22,365 shares during the period. 91.26% of the stock is owned by hedge funds and other institutional investors.

Orthofix International NV (NASDAQ:OFIX) traded down 0.89% during mid-day trading on Friday, reaching $40.25. 47,200 shares of the company traded hands. The firm’s market capitalization is $729.49 million. Orthofix International NV has a 52 week low of $32.25 and a 52 week high of $48.25. The stock’s 50 day moving average price is $43.62 and its 200 day moving average price is $43.81.

Orthofix International NV (NASDAQ:OFIX) last posted its quarterly earnings results on Monday, August 1st. The medical device company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.33 by $0.08. Orthofix International NV had a negative net margin of 0.37% and a positive return on equity of 8.50%. The company earned $104.10 million during the quarter, compared to analysts’ expectations of $102.40 million. During the same quarter in the previous year, the business posted $0.36 EPS. The firm’s revenue was up 3.1% on a year-over-year basis. Equities analysts forecast that Orthofix International NV will post $1.41 EPS for the current year.

OFIX has been the subject of several recent research reports. Zacks Investment Research raised shares of Orthofix International NV from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a report on Wednesday, June 29th. TheStreet cut shares of Orthofix International NV from a “buy” rating to a “hold” rating in a report on Wednesday, August 3rd.

In other Orthofix International NV news, insider Michael Finegan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $45.16, for a total transaction of $1,129,000.00. Following the completion of the transaction, the insider now owns 51,670 shares in the company, valued at approximately $2,333,417.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 5.10% of the company’s stock.

About Orthofix International NV

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Related posts

Leave a Comment